Delivery format matters. A child who is motivated by gaming may thrive with Eye Hero or Bynocs, while one who simply wants to watch their favorite show may be better suited for Luminopia or CureSight. A patient whose amblyopia persists into adulthood may gravitate toward RevitalVision’s cortical retraining approach. Whether treatment is delivered through a virtual reality headset or in free space with anaglyph glasses may also influence your patient’s binocularity, comfort, acceptance, and ultimately adherence. Your choice depends on your knowledge of each tool, its limitations, and, above all, your patient’s individual needs—because the right tool for one patient may not be the right one for the next. The clinical profile of each patient should also guide selection. A child struggling specifically with stereoacuity may benefit from a treatment with demonstrated outcomes in stereopsis. One with documented oculomotor deficits or poor handeye coordination may be best served by a platform that targets those functions directly. Understanding the age ranges studied in each clinical trial helps us match the evidence to the patient sitting in our chair. Conclusion As clinicians, our role is no longer simply to prescribe a patch and monitor acuity. We are now equipped to be thoughtful about which technology best addresses each patient’s specific visual profile, preferences, and goals. The more fluent we become in these tools, including their mechanisms, their evidence, and their limitations, the better positioned we are to individualize care. Amblyopia treatment has entered a new era, and our patients are better off for it. Optometry & Visual Performance 158 Volume 14 | Issue 2 | June 2026 Correspondence regarding this article should be emailed to Man Kin (Eric) Chow at drchow@miamivt.com. All statements are the author’s personal opinions and may not reflect the opinions of the representative organization, OEPF, Optometry & Visual Performance, or any institution or organization with which the author may be affiliated. Permission to use reprints of this article must be obtained from the editor. Copyright 2026 Optometric Extension Program Foundation. Online access is available at www.oepf.org and www.ovpjournal.org. Chow MK. Digital therapies for amblyopia. Optom Vis Perf 2026;14(2):154-8. References 1. Thompson B, Morrone MC, Bex P, Lozama A, Sabel BA. Harnessing brain plasticity to improve binocular vision in amblyopia: An evidence-based update. Eur J Ophthalmol 2024;34(4):901-12. 2. Magdalene D, Dutta P, Deshmukh S, Borah CJ, Nath RP. Neural vision perceptual learning as an effective treatment of amblyopia. Vision Dev Rehabil 2022;8(4):260-9. 3. Basoglu Y, Serbetcioglu MB, Cicek FD. AmblyoPlay-based multimodal visual therapy in pediatric anisometropic amblyopia: A pilot study of visual, oculomotor and sensorimotor outcomes. BMC Ophthalmol 2025;25:648. doi:10.1186/s12886-025-04481-2. 4. Wygnanski-Jaffe T, Moshkovitz A, Kushner BJ, Belkin M, Yehezkel O; CureSight Pivotal Trial Group. Binocular home treatment for amblyopia: Gains stable for one year. Am J Ophthalmol 2024;262:199-205. 5. Xiao S, Angjeli E, Wu HC, Gaier ED, et al. Luminopia Pivotal Trial Group. Randomized controlled trial of a dichoptic digital therapeutic for amblyopia. Ophthalmol 2022;129(1):77-85. 6. Abdal MO, Bhombal F, Nankani GJ, Nankani SG, et al. Evaluation of the efficacy of a new dichoptic digital platform to treat the anisometropic and isometropic amblyopia. Brain Sci 2022;12(7):815. doi:10.3390/brainsci12070815. 7. Ganesh S, Lusobya RC, Balasubramanian J, Jogitha, et al. Effectiveness of dichoptic therapy for treating mild to moderate amblyopia in a tertiary eye care center in South India. J Pediatr Ophthalmol Strabismus 2024;61(6):416-424. doi:10.3928/01913913-20240521-03. 8. Wygnanski-Jaffe T, Kushner BJ, Moshkovitz A, Belkin M, Yehezkel O; CureSight Pivotal Trial Group. An eye-trackingbased dichoptic home treatment for amblyopia: A multicenter randomized clinical trial. Ophthalmol 2023;130(3):274-85. 9. Hecht I, Yahalom C, Abaev O, Einan-Lifshitz A, et al. Efficacy of perceptual learning among patients with infantile nystagmus: A prospective single-blind randomised controlled trial. Br J Ophthalmol 2025. doi:10.1136/bjo-2025-328227. 10. Polat U, Ma-Naim T, Belkin M, Sagi D. Improving vision in adult amblyopia by perceptual learning. Proc Natl Acad Sci 2004;101(17):6692-7.
RkJQdWJsaXNoZXIy MjEyMDQ0Nw==